Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has earned an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $21.3750.

A number of equities analysts have weighed in on KROS shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 22nd. Wedbush increased their price target on Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Zacks Research upgraded Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Bank of America lifted their price objective on Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. Finally, Wells Fargo & Company cut their target price on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th.

Keros Therapeutics Stock Down 1.5%

Shares of NASDAQ:KROS opened at $21.03 on Friday. The company has a market capitalization of $640.78 million, a price-to-earnings ratio of 13.66, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. The company has a 50 day moving average of $18.06 and a two-hundred day moving average of $15.85. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The business had revenue of $14.26 million during the quarter, compared to the consensus estimate of $4.22 million. During the same period in the prior year, the firm earned ($1.41) earnings per share. The business’s quarterly revenue was up 3585.6% compared to the same quarter last year. On average, equities analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Insider Activity

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. Additional details regarding this sale are available in the official SEC disclosure. 20.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Jump Financial LLC acquired a new stake in Keros Therapeutics in the first quarter worth $1,058,000. Assenagon Asset Management S.A. boosted its holdings in shares of Keros Therapeutics by 56.0% during the second quarter. Assenagon Asset Management S.A. now owns 101,297 shares of the company’s stock valued at $1,352,000 after acquiring an additional 36,360 shares during the period. Invesco Ltd. boosted its holdings in shares of Keros Therapeutics by 163.7% during the first quarter. Invesco Ltd. now owns 33,266 shares of the company’s stock valued at $339,000 after acquiring an additional 20,650 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the last quarter. Finally, DRW Securities LLC bought a new position in shares of Keros Therapeutics during the first quarter worth about $4,737,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.